The Medical Letter on Drugs and Therapeutics
				
			FROM
ISSUE 1467
    
   			ISSUE 1467
April 27, 2015
                			
                		 Issue 1467
                		- Carbidopa/Levodopa Extended-Release Capsules (Rytary)
 - Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting
 - Umeclidinium (Incruse Ellipta) for COPD
 - Glyxambi - A New Combination for Type 2 Diabetes
 - Addendum: Diet, Drugs, and Surgery for Weight Loss
 - In Brief: Mechlorethamine Gel (Valchlor) for Cutaneous T-Cell Lymphoma (online only)
 
					Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
				
				Carbidopa/Levodopa Extended-Release Capsules (Rytary)
April 27, 2015 (Issue: 1467)
				The FDA has approved a new formulation of carbidopa/levodopa (Rytary – Impax) in extended-release capsules for treatment of Parkinson’s disease (PD).
        			
        			
					
					
				
        			
				The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
				